Home / Health care / Adair demonstrated a new technology she thinks could democratize access to gene therapy
alibaba.com, cpa campaign, lead generation, lead campaign, smart match lander, intelligent lander, a

Adair demonstrated a new technology she thinks could democratize access to gene therapy

as declared in In October, Adair demonstrated a new technology she thinks could democratize access to gene therapy.
Gene therapy is moving quickly from experiment to medical reality.
Gotwals expects that, at first, gene therapy in a box will be useful to companies that want to expand manufacturing, or to academic centers that want to start offering it.
“We want to make cell therapy less elite than it is right now.
Adair calls the mobile lab “gene therapy in a box.”Adair thinks a key job for the mobile gene-therapy lab is to extend experimental studies to the developing world, including Africa, where most HIV cases are.

This Lab-in-a-Box Could Make Gene Therapy Less Elitist

according to The idea of having some kind of portable gene therapy treatment was conceptualized by Dr. Adair back in 2009.
Swiss drug company Novartis AG (ADR)(NYSE:NVS) is one of the first to explore this type of automated and portable gene therapy approach.
The new technology was demonstrated last October through a gene therapy for HIV that their team was testing.
In its initial version, the device was able to separate stem cells from other blood cells using metal beads and magnets.
By automating CAR-T production using the instrument developed by Dr. Adair and colleagues, gene therapy treatment that is generally complex and expensive can potentially be transformed into a simple and affordable process.

according to

Tocagen Plans IPO to Finance Trials of Gene Therapy in Brain Cancer

Tocagen Plans IPO to Finance Trials of Gene Therapy in Brain CancerXconomy San Diego —[Corrected 3/10/17, 3:27 pm.
Tocagen has treated 126 brain cancer patients with its gene therapy approach in three dose-ranging Phase 1 clinical trials.
See below] Gene therapy developer Tocagen is preparing an initial public stock offering to finance clinical trials of its experimental treatment for a form of brain cancer.
The core technology that forms the basis for Tocagen’s gene therapy was licensed from the University of Southern California.
The idea is to use the two components to turn cancer cells into tiny factories churning out anti-cancer agents.

This content may collect you by Victoria Hunter

To follow all the new news about Therapy

Check Also

C-QAQNFXsAAEGmF

Cancer disease Patient Injected by pollen For The premier Time

as declared in Cancer disease Patient Injected by pollen For The premier Time Saturday, November …